Abstracts tagged "gout"

Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
James Cheng-Chung Wei¹, Roy Fleischmann², sarah Morris³, Vijay Hingorani⁴, Elizabeth Polvent⁵, Zancong Shen⁶, Shunqi Yan⁷, Li-Tain Yeh⁸ and Robert Keenan⁹, ¹Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ²Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Arthrosi Therapeutics, San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁸Arthrosi Therapeutics, Inc., Irvine, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
Abstract Number: 1120 • ACR Convergence 2023
Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Natalie McCormick¹, Chio Yokose², Gregory Challener¹, Amit Joshi³, Sruthi Tanikella¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Channing Division of Network Medicine, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…
Abstract Number: 0049 • ACR Convergence 2023
Soluble Uric Acid Is an Endogenous Inhibitor of CD38
Shijie Wen¹, Hiroshi Arakawa¹, Shigeru Yokoyama², Yoshiyuki Shirasaka¹, Haruhiro Higashida³ and Ikumi Tamai¹, ¹Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan, ²Research Center for Child Mental Development, Kanazawa University; Division of Socio-Cognitive-Neuroscience, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Kanazawa University, Kanazawa, Japan, ³Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan
Background/Purpose: CD38 is the main NAD+-degrading enzyme that plays a key role in innate immunity, aging, cancer, and metabolic disorders. Pharmacological inhibition of CD38 has…
Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Claudia Maria Gomez¹, Patricio Cardoso Peñafiel¹, Jose Antonio Angel-Sesmero¹, Marta Novella-Navarro² and Enrique Calvo-Aranda¹, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
Abstract Number: 1037 • ACR Convergence 2023
Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy
Adwoa Dansoa Tabi-Amponsah¹, Sarah Stewart², Greg Gamble¹, Anthony Doyle³, Chang-Nam Son⁴, Kieran Latto¹, Lisa Stamp⁵, William Taylor⁶, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland University of Technology, Auckland, New Zealand, ³Auckland District Health Board and University of Auckland, Auckland, New Zealand, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ⁵University of Otago, Christchurch, New Zealand, ⁶University of Otago, Wellington, New Zealand
Background/Purpose: Preliminary gout remission criteria have been developed using OMERACT core outcome domains for long-term gout studies. This study aimed to identify variables that predict…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…
Abstract Number: 0058 • ACR Convergence 2023
Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation
Douglas Daoudlarian¹, André Tiaden², Stavros Giaglis³, Ulrich Walker⁴, Petr Broz⁵, Tobias Maningold⁶ and Diego Kyburz¹, ¹University Hospital Basel, Basel, Switzerland, ²Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ³University of Basel/University Hospital of Basel, Basel, Switzerland, ⁴Basel University Hospital, Basel, Switzerland, ⁵University of Lausanne, Lausanne, Switzerland, ⁶Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland
Background/Purpose: Monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals are potent inducers of inflammation by activation of the inflammasome in neutrophils phagocytosing the crystals and…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 1102 • ACR Convergence 2023
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Amy S. Mudano¹, Jessica Ryan¹, Emily Holladay², Kathleen Methric³, Danielle Grauer⁴, Brian LaMoreaux³, Fenglong Xie¹ and Jeffrey R Curtis⁵, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Horizon Therapeutics, Deerfield, IL, ⁴Illumination Health, Boca Raton, FL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: Treatment of patients with gout can be complex and, given the episodic nature of gout attacks, gout patients may not always return for regular…
Abstract Number: 1122 • ACR Convergence 2023
The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy
Cindy Cao¹, Greg Gamble¹, Anne Horne¹, Opetaia Aati¹, Anthony Doyle¹, Jill Drake², Lisa Stamp³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Te Whatu Ora Waitaha, Christchurch, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: In 2015, the 20-item Tophus Impact Questionnaire (TIQ-20) was developed as a tophus-specific patient reported outcome measure (Aati et al., 2015). Initial analysis of…
Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Tate Johnson¹, Lindsay Helget², Harlan Sayles², Punyasha Roul³, James O'Dell², Ted Mikuls⁴ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
Abstract Number: 1797 • ACR Convergence 2022
Factors Driving Opioid Use in United States Veterans with Gout
Lindsay Helget¹, Bryant England¹, Punyasha Roul², Harlan Sayles¹, Alison Petro¹, Tuhina Neogi³, James O'Dell¹ and Ted Mikuls⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³Boston University School of Medicine, Boston, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with gout often seek care for painful flares and nearly one-third are prescribed opioids during acute ambulatory visits. Unfortunately, opioids do not address…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].